Navitoclax enhances the effectiveness of EGFR-targeted antibody-drug conjugates in PDX models of EGFR-expressing triple-negative breast cancer

BACKGROUND: Targeted therapies for triple-negative breast cancer (TNBC) are limited; however, the epidermal growth factor receptor (EGFR) represents a potential target, as the majority of TNBC express EGFR. The purpose of these studies was to evaluate the effectiveness of two EGFR-targeted antibody-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Cancer Res
Main Authors: Zoeller, Jason J., Vagodny, Aleksandr, Daniels, Veerle W., Taneja, Krishan, Tan, Benjamin Y., DeRose, Yoko S., Fujita, Maihi, Welm, Alana L., Letai, Anthony, Leverson, Joel D., Blot, Vincent, Bronson, Roderick T., Dillon, Deborah A., Brugge, Joan S.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7708921/
https://ncbi.nlm.nih.gov/pubmed/33256808
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13058-020-01374-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados